1. Home
  2. EME vs INSM Comparison

EME vs INSM Comparison

Compare EME & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EME
  • INSM
  • Stock Information
  • Founded
  • EME 1987
  • INSM 1988
  • Country
  • EME United States
  • INSM United States
  • Employees
  • EME N/A
  • INSM N/A
  • Industry
  • EME Engineering & Construction
  • INSM Biotechnology: Pharmaceutical Preparations
  • Sector
  • EME Industrials
  • INSM Health Care
  • Exchange
  • EME Nasdaq
  • INSM Nasdaq
  • Market Cap
  • EME 21.2B
  • INSM 17.3B
  • IPO Year
  • EME N/A
  • INSM 2000
  • Fundamental
  • Price
  • EME $531.08
  • INSM $99.95
  • Analyst Decision
  • EME Buy
  • INSM Strong Buy
  • Analyst Count
  • EME 5
  • INSM 17
  • Target Price
  • EME $501.60
  • INSM $106.80
  • AVG Volume (30 Days)
  • EME 447.0K
  • INSM 6.0M
  • Earning Date
  • EME 07-24-2025
  • INSM 08-07-2025
  • Dividend Yield
  • EME 0.19%
  • INSM N/A
  • EPS Growth
  • EME 49.21
  • INSM N/A
  • EPS
  • EME 22.63
  • INSM N/A
  • Revenue
  • EME $15,001,212,000.00
  • INSM $381,030,000.00
  • Revenue This Year
  • EME $14.10
  • INSM $28.03
  • Revenue Next Year
  • EME $5.69
  • INSM $120.54
  • P/E Ratio
  • EME $23.66
  • INSM N/A
  • Revenue Growth
  • EME 14.30
  • INSM 20.77
  • 52 Week Low
  • EME $319.49
  • INSM $60.40
  • 52 Week High
  • EME $545.30
  • INSM $106.83
  • Technical
  • Relative Strength Index (RSI)
  • EME 78.17
  • INSM 70.94
  • Support Level
  • EME $478.16
  • INSM $98.46
  • Resistance Level
  • EME $493.39
  • INSM $106.83
  • Average True Range (ATR)
  • EME 11.14
  • INSM 3.81
  • MACD
  • EME 2.71
  • INSM 1.13
  • Stochastic Oscillator
  • EME 98.17
  • INSM 85.96

About EME EMCOR Group Inc.

EMCOR Group Inc is a specialty contractor in the United States and a provider of electrical and mechanical construction and facilities services, building services, and industrial services. Its services are provided to a broad range of commercial, technology, manufacturing, industrial, healthcare, utility, and institutional customers through approximately 100 operating subsidiaries. The company's operating subsidiaries are organized into reportable segments: United States mechanical construction and facilities services, which derives key revenue; United States electrical construction and facilities services; United States building services; United States industrial services; and United Kingdom building services. Geographically, its key revenue is derived from the United States.

About INSM Insmed Incorporated

Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.

Share on Social Networks: